Tumor-rechallenge experiments in previous preclinical studies showed complete tumor rejection as well as increased antigen-specific memory CD8+ T-cells in mice that cleared initial tumors after combination therapy of RT and anti–PD-1/PD-L1 (26, 53). The gene discussed is CD8A; the disease is neoplasm.